Translational Medicine Research Collaboration announces first round research project funding
The Translational Medicine Research Collaboration (TMRC) announced the first round of research projects to be funded through the new £50 million initiative. Almost £8 million of funding has been released to support 28 new research projects covering a wide range of therapeutic areas including cardiovascular and metabolic disease, the central nervous system, oncology, inflammation, and women's health.
The Collaboration comprises four of Scotland's leading universities (Aberdeen, Dundee, Edinburgh and Glasgow), Wyeth Pharmaceutical Co, Scottish Enterprise and NHS Scotland Grampian, Greater Glasgow, Lothian and Tayside, and provides new impetus for Scotland in the development of personalised medicine, bringing new treatments to patients suffering from a range of serious illnesses.
Professor Andrew Morris, chair of the TMRC Steering Group, said: "This first large injection of medical research funding into Centres of Excellence across Scotland is an important milestone for TMRC. The spirit of collaboration between the partners has been fantastic, and we have already set our sights on supporting more researchers in innovative ways in the months ahead."
Further projects to be funded through TMRC are already in the pipeline and applications for a second round of funding are being invited from the scientific community in Scotland.
Other news from the department science
